NDAORALCAPSULE
Approved
Dec 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
LYRICA (pregabalin) by Teva is 2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. First approved in 2004.
Drug data last refreshed 11h ago · AI intelligence enriched 13h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYRICA (pregabalin) is an oral small-molecule anticonvulsant that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. It reduces calcium-dependent release of pro-nociceptive neurotransmitters and modulates pain transmission via descending noradrenergic and serotonergic pathways. It is indicated for neuropathic pain, fibromyalgia, and post-herpetic neuralgia.
$0.072BPart D
LOE ApproachingApproaching loss of exclusivity with 75K+ annual claims signals declining team growth and shift toward defensive positioning and generic transition planning.
Mechanism of Action
2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Indications
Worked on LYRICA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.